Search company, investor...

Fusion Medical Technologies

Stage

Acq - P2P | Acquired

Total Raised

$18.51M

Valuation

$0000 

About Fusion Medical Technologies

Fusion is developing surgical sealants for procedures which initially include those in cardiovascular, vascular, orthopedics, and neurosurgery specialties. Acquired by Baxter BioScience.

Headquarters Location

Missing: Fusion Medical Technologies's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Fusion Medical Technologies's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Fusion Medical Technologies Patents

Fusion Medical Technologies has filed 3 patents.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

12/21/2017

7/28/2020

Vascular diseases, Hematology, Interventional radiology, Systemic risk, Coagulopathies

Grant

Application Date

12/21/2017

Grant Date

7/28/2020

Title

Related Topics

Vascular diseases, Hematology, Interventional radiology, Systemic risk, Coagulopathies

Status

Grant

Latest Fusion Medical Technologies News

Baxter Completes Acquisition of Fusion Medical Technologies

May 13, 2016

Broad Clinical Applications of Fusion's Hemostat Complements Baxter's Strength in Tissue Sealing and Expands Surgical Channels May 03, 2002, 01:00 ET from Baxter International Inc. DEERFIELD, Ill., May 3 /PRNewswire-FirstCall/ -- Baxter International Inc. (NYSE: BAX) announced today that it has completed its acquisition of Fusion Medical Technologies (Nasdaq: FSON) for approximately $157 million of Baxter common stock in a stock-for-stock merger. Baxter has begun the process of integrating Fusion and anticipates a seamless transition for customers and its approximately 100 employees. "By joining forces with Fusion, Baxter takes another step forward in playing a broader and more vital role in the biosurgery market," said Greg Bosch, general manager of Baxter's BioSurgery business, noting Fusion's expertise in developing and commercializing proprietary products used to control bleeding during surgery. "We believe that Fusion's talents and expertise in collagen/gelatin-based products complement our strategic focus on providing innovative therapeutic solutions for biosurgery and tissue regeneration. Most importantly, we believe that combining the businesses should accelerate the clinical adoption of both Tisseel fibrin sealant and FloSeal matrix hemostatic sealant, for the ultimate benefit of patients worldwide. " Fusion's primary commercial product, FloSeal matrix, is a combination of specially engineered collagen-derived particles and topical thrombin that is very effective in controlling bleeding. It is easy to use and works well on wet, actively bleeding tissue, even in very challenging situations. The FDA approved the sale of FloSeal in the United States in December 1999. Fusion currently markets the FloSeal products in surgical procedures, other than ophthalmic, as an adjunct to hemostasis when control of bleeding by ligature or conventional procedures is ineffective or impractical. Tisseel VH fibrin sealant, Baxter's principal biosurgery product, was the first fibrin sealant to receive FDA approval and is indicated for tissue sealing, as well as hemostasis in cardiopulmonary procedures. Introduced in Europe, Tisseel (also marketed as Tissucol fibrin sealant in some countries) is backed by more than twenty-two years of clinical experience and has been used in more than 8 million surgical procedures worldwide. Baxter's BioScience business develops and produces biopharmaceuticals, vaccines, and innovative therapeutic solutions for biosurgery and tissue regeneration, including fibrin sealant and a complete line of application devices. Baxter International Inc. is a global health care company that, through its subsidiaries, provides critical therapies for people with life-threatening conditions. Baxter's bioscience, medication delivery and renal products and services are used to treat patients with some of the most challenging medical conditions including cancer, hemophilia, immune deficiencies, infectious diseases, kidney disease and trauma. (Tisseel and Tissucol are trademarks of Baxter International Inc. or Baxter AG. Tisseel is registered in the U.S. Patent and Trademark office. ) (Fusion Medical Technologies, Fusion, FloSeal, and the stylized Fusion logo are trademarks of Fusion. ) This press release contains forward-looking statements that involve risks and uncertainties, including technological advances in the medical field, product demand and market acceptance, the effect of economic conditions, the impact of competitive products and pricing, actions of regulatory bodies and other risks detailed in the company's filings with the SEC. These forward- looking statements are based on estimates and assumptions made by management of Baxter at the time of issuance of this press release, that are believed to be reasonable, but are inherently uncertain and difficult to predict. Actual results or experience could differ materially from the forward-looking statements. MAKE YOUR OPINION COUNT - Click Here http://tbutton.prnewswire.com/prn/11690X13944352 SOURCE Baxter International Inc.

Fusion Medical Technologies Frequently Asked Questions (FAQ)

  • What is Fusion Medical Technologies's latest funding round?

    Fusion Medical Technologies's latest funding round is Acq - P2P.

  • How much did Fusion Medical Technologies raise?

    Fusion Medical Technologies raised a total of $18.51M.

  • Who are the investors of Fusion Medical Technologies?

    Investors of Fusion Medical Technologies include Baxter International, Alloy Ventures, Domain Associates and Asset Management Ventures.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.